Latest Hagop Kantarjian Stories
The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care.
MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy.
Two drugs approved for treatment of drug-resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication.
- A transitional zone between two communities containing the characteristic species of each.